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eAppendix. Inclusion and Exclusion Criteria
Key Inclusion Criteria 1. Men or women between 18 and 75 years of age, inclusive, at time of informed consent 2. Patients willing and able to comply with scheduled visits, treatment plan, laboratory testing, and other study procedures 3. Men able to father children and women of childbearing potential and at risk for pregnancy had to agree to use a highly effective method of contraception throughout the study and for ≥28 days after the last dose of study treatment 4. Met the following atopic dermatitis criteria:
a. Clinical diagnosis of chronic atopic dermatitis for ≥1 year before day 1 and confirmed atopic dermatitis (Hanifin and Rajka criteria 1 of atopic dermatitis) at the screening visit b. Inadequate response to treatment with topical medications (topical corticosteroids or topical calcineurin inhibitors) given for ≥4 weeks or unable to receive topical treatment within 12 months before the first dose of study drug because it was otherwise medically inadvisable (eg, application to a large %BSA which is associated with increased risk for systemic absorption and hypothalamic-pituitary-adrenal axis suppression, cutaneous side effects such as burning or stinging sensations with topical calcineurin inhibitors or skin atrophy, purpura, telangiectasia, and striae with chronic use of topical corticosteroids) c. Moderate-to-severe atopic dermatitis (percentage of affected body surface area ≥10, investigator's global assessment score ≥3, and Eczema Area and Severity Index score ≥12 at the screening and baseline visits) 5. Had to agree to avoid prolonged exposure to the sun and not to use tanning booths, sun lamps, or other ultraviolet light sources during the study 6. If receiving concomitant medications for any reason other than atopic dermatitis, had to be on a stable regimen, defined as not starting a new drug or changing dosage within 7 days or 5 half-lives (whichever was longer) before day For discontinued patients, any missing value for all subsequent visits until week 12 was imputed using the nonresponder imputation approach. Baseline was defined as the last measurement before first dosing. Emax denotes the difference between maximum achievable response (at infinite dose) and baseline.
eFigure 4. Proportion of Patients With Baseline Pruritus NRS Score of ≥4

Achieving ≥4-Point Improvement From Baseline Over the First 2 Weeks
A logistic regression model was used including treatment as a main effect and baseline score as a covariate. Bars denote 90% CIs. For discontinued patients, any missing value for all subsequent visits until week 12 was imputed using the nonresponder imputation approach. Baseline was defined as the last measurement before first dosing. NRS, numeric rating scale.
eFigure 5. Photographic Evidence
Representative photographs at day 1, week 4, and week 12 are presented for patients treated with placebo, 100 mg abrocitinib, and 200 mg abrocitinib. 
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